ARJUNA Therapeutics

📍 Milladoiro, A Coruña, Spain🗓 Founded 2019👥 10 employees💰 Last funded Jul 2019
Pharmaceutical Manufacturing
LinkedIn
We are developing an entirely novel class of orally available small molecules to address untreatable cancers. Our first drug, Ag5, aims to redefine the treatment landscape for solid tumours on both sides of the blood brain barrier by targeting the 30% of all cancers that generate high levels of Reactive Oxygen Species. This large group contains cancers driven by mutations in the KRAS gene, triple negative breast cancer and glioblastoma-all of which are urgent unmet medical needs with large potential markets. We have a deep pipeline of follow on medicines. Our goal is to revolutionise cancer treatment for patients and their doctors.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2018–2019 · investors recorded per year
2018120192
Recent (last 2y)Earlier
Frequently asked questions
Who invested in ARJUNA Therapeutics?
ARJUNA Therapeutics has 3 investors on record on gritt.io, including 3 early-stage backers.
When did ARJUNA Therapeutics last raise funding?
The most recent investment in ARJUNA Therapeutics recorded on gritt.io was in July 2019.
When was ARJUNA Therapeutics founded?
ARJUNA Therapeutics was founded in 2019.
What industry is ARJUNA Therapeutics in?
ARJUNA Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is ARJUNA Therapeutics based?
ARJUNA Therapeutics is headquartered in Milladoiro, A Coruña, Spain.